Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

49.44
-0.1200-0.24%
Post-market: 49.440.00000.00%19:58 EDT
Volume:715.47K
Turnover:35.63M
Market Cap:3.03B
PE:11.69
High:50.52
Open:49.33
Low:49.33
Close:49.56
Loading ...

Protagonist Therapeutics Inc - Impact on Takeda's FY2024 Financial Results Is Immaterial

THOMSON REUTERS
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire
·
03 Mar

Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships

TIPRANKS
·
28 Feb

Protagonist Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Protagonist Therapeutics Reports Strong 2024 Financial Results

TIPRANKS
·
25 Feb

Protagonist Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
25 Feb

Stock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships

Stock Track
·
24 Feb

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
24 Feb

Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Feb

Protagonist Therapeutics Faces Financial Risks Amidst Growing Pharmaceutical Pricing Pressures

TIPRANKS
·
23 Feb

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Simply Wall St.
·
22 Feb

Protagonist Therapeutics Poised for Growth with Strong Data Prospects and Robust Financial Position

TIPRANKS
·
22 Feb

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

Reuters
·
22 Feb

BUZZ-Protagonist Therapeutics rises on quarterly profit beat

Reuters
·
21 Feb

Protagonist Therapeutics Shares up 3% After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks
·
21 Feb